Search results
Showing 121 to 135 of 711 results for medication
Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (HTG653)
Evidence-based recommendations on transcutaneous electrical stimulation of the trigeminal nerve for ADHD. This involves a single-use electrode patch stuck to the forehead, which sends small electrical pulses through the skin during sleep.
View recommendations for HTG653Show all sections
Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in adults.
Show all sections
Trabecular stent bypass microsurgery for open-angle glaucoma (HTG432)
Evidence-based recommendations on trabecular stent bypass microsurgery for open-angle glaucoma. This involves inserting a hollow metal tube (stent) into the eye, to improve drainage of fluid from the eye.
Transition between inpatient mental health settings and community or care home settings (NG53)
This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.
Ab externo canaloplasty for primary open-angle glaucoma (HTG448)
Evidence-based recommendations on ab externo canaloplasty for primary open-angle glaucoma in adults. This involves widening the eye’s main draining canal by inserting a tiny tube, then removing the tube and stitching the canal to keep it open.
This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
This indicator covers the percentage of patients with heart failure on the register, who had a review in the preceding 12 months, including an assessment of functional capacity (using the New York Heart Association classification) and a review of medication. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM174
Recommendation ID NG80/10 Question Improving adherence to asthma medication:- What are the most clinically and cost-effective strategies...
Devices for remote monitoring of Parkinson's disease (HTG657)
Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.
Evidence-based recommendations on cryotherapy for chronic rhinitis. This involves destroying a nerve in the nose to reduce chronic rhinitis symptoms.
View recommendations for HTG692Show all sections
Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain (HTG652)
Evidence-based recommendations on percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. This involves using a needle-like probe to freeze and destroy small parts of nerves in neuromas to stop the pain signals.
View recommendations for HTG652Show all sections
This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Bipolar, schizophrenia and other psychoses: annual cholesterol (IND158)
This indicator covers the percentage of patients aged 18 years and over with schizophrenia, bipolar affective disorder and other psychoses who have a record of total cholesterol: hdl ratio in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM129